REFRACTORY LYMPHOMA
Clinical trials for REFRACTORY LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vitamin c boost: could high doses help chemo fight tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 14:46 UTC
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trial
Disease control Recruiting nowThis study tests an experimental drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink t…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 15, 2026 14:39 UTC
-
Engineered immune cells take on hard-to-treat lymphoma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 15, 2026 14:36 UTC
-
New drug cocktail aims to shrink Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests whether a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) can safely shrink tumors in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. About 45 adults who have already tried at…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Triple-Drug attack shows promise against tough blood cancer
Disease control Recruiting nowThis study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma, a type of blood cancer. It includes both patients whose cancer has returned or not responded to treatment, and those who have not yet been treated. Th…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Austin I Kim • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 par…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 03, 2026 12:05 UTC
-
New CAR-T therapy takes aim at stubborn leukemia and lymphoma
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a …
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 01, 2026 17:57 UTC